-Takeshi Niizeki Researcher Activity Profile

Research Author Detailed Information 

Takeshi Niizeki Publication Rate By Year

Takeshi Niizeki has published 10 paper(s) in 2007, 3 paper(s) in 2008, for a total of 13 research publications in total.

Takeshi T Niizeki Author Information

LAST NAME: niizeki

FIRST NAME: takeshi

INITIALS: T

AFFILIATION:

Papers

Takeshi Niizeki's Publication Record

1. Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan. takeishi@med.id.yamagata-u.ac.jp
2. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
3. Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
4. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
5. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
6. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
7. Persistently increased serum concentration of heart-type Fatty Acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine.
8. Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
9. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
10. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Year Published: 2007
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
11. Diacylglycerol Kinase zetaRescues Galphaq-Induced Heart Failure in Transgenic Mice. Year Published: 2008
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine.
12. Diacylglycerol kinase zeta rescues G alpha q-induced heart failure in transgenic mice. Year Published: 2008
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
13. Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. Year Published: 2008
Department of Cardiology, Pulmonology and Nephrology, Yamagata University School of Medicine, Yamagata, Japan. obilim@med.id.yamagata-u.ac.jp